Loading...
•
Mar 31, 2024
Chemed Q1 2024 Earnings Report
Chemed's Q1 2024 performance was marked by revenue growth and increased EPS, with VITAS Healthcare driving revenue while Roto-Rooter faced revenue decline.
Key Takeaways
Chemed Corporation reported a 5.2% increase in revenue to $589.2 million and a GAAP diluted EPS of $4.24, up 18.4%. Adjusted diluted EPS increased by 21.5% to $5.20. VITAS Healthcare saw a 14.0% increase in net patient revenue, while Roto-Rooter experienced a 5.8% decrease in revenue.
Consolidated revenue increased by 5.2% to $589.2 million.
GAAP diluted EPS rose by 18.4% to $4.24.
VITAS Healthcare's net patient revenue increased by 14.0%.
Roto-Rooter's revenue decreased by 5.8%.
Chemed
Chemed
Chemed Revenue by Segment
Revenue by Segment
VITAS Revenue
CapyFin.comRoto-Rooter Revenue
CapyFin.com Forward Guidance
Management reiterates its estimated full-year 2024 earnings per diluted share guidance range of $23.30 to $23.70, excluding certain items, and anticipates providing updated 2024 earnings guidance and related subsidiary operating metrics as part of the June 30, 2024 earnings press release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income